期刊文献+

炎症影响药物转运体表达及活性研究进展 被引量:8

Progress and research about effects of inflammation on expression and activity of drug transporters
下载PDF
导出
摘要 伴随机体炎症因子大量释放,药物转运体表达及活性发生了改变,进而影响了药物吸收、分布、转化及消除过程,这会使药物产生毒性或疗效变化,亦会导致药物—药物相互作用发生。该文就炎症相关因素影响药物转运体表达、活性、可能机制及临床应用最新研究进展进行综述,以期为炎症调节转运体研究指明方向。 The expression and activity of some drug transporters are regulated by inflammatory factor during its release.Concomitantly,the processes of drug absorption,distribution,transformation and elimination are also influenced.After that,the drug toxicity occurs or drug efficacy decreases,which even leads to drug-drug interactions.This review summarizes the possible mechanisms,clinical application and effects of inflammation on expression and activity of drug transporters to guide the direction for its further research.
出处 《中国药理学通报》 CAS CSCD 北大核心 2011年第1期7-10,共4页 Chinese Pharmacological Bulletin
基金 国家重大新药创制专项资助(No2009ZX09304-003,2009ZX09501-032) 国家自然科学基金资助项目(No30801421,30901834) 中南大学基本科研业务重点项目(No2010QZZD010)
关键词 炎症诱导物 促炎细胞因子 抗炎药物 药物转运体 调节机制 临床应用 inflammatory inducer inflammatory cytokines anti-inflammatory drugs drug transporters regulatory mechanism clinical application
  • 相关文献

参考文献5

二级参考文献93

  • 1Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 2005; 22: 1559-77.
  • 2Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
  • 3Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8.
  • 4Chen C, Mireles R J, Campbell SD, Lin J, Mills JB, Xu J J, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-Coa reductase inhibitors with ABCB1, ABCC2, and OATPIBI. Drug Metab Dispos 2005; 33: 537-46.
  • 5Wu X, Whitfieid LR, Stewart BH. Atorvastatintransport in the Caco-2 cell model: contributions of P-glycoprotein and the protonmonocarboxylic acid co-transporter. Pharm Res 2000; 17: 209-15.
  • 6Rodrigues AC, Curi R, Britto LR, Rebbechi IM, Hirata MH, Bertolami MC, et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta 2006; 1760: 1866-73.
  • 7Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-80.
  • 8Maiiepaard M, Scheffer GL, Faneyte IF, Van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-64.
  • 9Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
  • 10Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.

共引文献28

同被引文献104

引证文献8

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部